Restricted expression of an adenoviral vector encoding fas ligand (CD95L) enhances safety for cancer gene therapy

Kazunori Aoki, Levent M. Akyürek, Hong San, Kwanyee Leung, Michael S. Parmacek, Elizabeth G. Nabel, Gary J. Nabel

Research output: Contribution to journalArticle

Abstract

Gene transfer of Fas ligand (CD95L) using adenoviral vectors has been shown to generate apoptotic responses and potent inflammatory reactions that can be used to induce the regression of malignancies in vivo, but these vectors also cause significant hepatotoxicity that may limit their clinical utility. Here we describe an adenoviral vector encoding CD95L with restricted gene expression that reduces itstoxicity in vivo. Preclinical efficacy and gene expression studies of lineage-restricted CD95L adenoviral vectors were performed. To enhance its cytotoxicity and reduce potential systemic effects, a noncleavable CD95L was made by deleting a segment containing the cleavage site (CD95LΔQP). Higher CD95L expression of this mutant was observed on the tumor cell surface, together with a reduction in the release of soluble CD95L This CD95L cleavage mutant was then expressed under control of a smooth muscle-specific promoter, SM22α, and analyzed for its ability to suppress the growth of tumors of smooth muscle origin in vivo. Growth of human leiomyosarcomas but not gliomas was inhibited after ADV gene transfer into tumor-bearing immunodeficient mice. In contrast to viral promoters, in which mortality was uniformly seen after injection of 1012 particles, no significant hepatic injury or systemic toxicity was observed in mice, and the maximum tolerated dose was increased ≥10-to 100-fold. These findings suggest that restricted specif icity of adenoviral CD95Lgene expression enhances the safety of this approach for cancer gene therapy.

Original languageEnglish (US)
Pages (from-to)555-565
Number of pages11
JournalMolecular Therapy
Volume1
Issue number6
StatePublished - Jun 2000
Externally publishedYes

Fingerprint

Fas Ligand Protein
Neoplasm Genes
Genetic Therapy
Safety
Smooth Muscle Tumor
Gene Expression
Neoplasms
Maximum Tolerated Dose
Leiomyosarcoma
Growth
Glioma
Genes
Smooth Muscle
Injections
Mortality
Liver
Wounds and Injuries

Keywords

  • Adenoviral vectors
  • Cancer gene therapy
  • CD95L
  • Cleavage mutant
  • Fas ligand
  • Leiomyosarcoma
  • SM22α promoter
  • Smooth muscle cell

ASJC Scopus subject areas

  • Molecular Biology

Cite this

Aoki, K., Akyürek, L. M., San, H., Leung, K., Parmacek, M. S., Nabel, E. G., & Nabel, G. J. (2000). Restricted expression of an adenoviral vector encoding fas ligand (CD95L) enhances safety for cancer gene therapy. Molecular Therapy, 1(6), 555-565.

Restricted expression of an adenoviral vector encoding fas ligand (CD95L) enhances safety for cancer gene therapy. / Aoki, Kazunori; Akyürek, Levent M.; San, Hong; Leung, Kwanyee; Parmacek, Michael S.; Nabel, Elizabeth G.; Nabel, Gary J.

In: Molecular Therapy, Vol. 1, No. 6, 06.2000, p. 555-565.

Research output: Contribution to journalArticle

Aoki, K, Akyürek, LM, San, H, Leung, K, Parmacek, MS, Nabel, EG & Nabel, GJ 2000, 'Restricted expression of an adenoviral vector encoding fas ligand (CD95L) enhances safety for cancer gene therapy', Molecular Therapy, vol. 1, no. 6, pp. 555-565.
Aoki K, Akyürek LM, San H, Leung K, Parmacek MS, Nabel EG et al. Restricted expression of an adenoviral vector encoding fas ligand (CD95L) enhances safety for cancer gene therapy. Molecular Therapy. 2000 Jun;1(6):555-565.
Aoki, Kazunori ; Akyürek, Levent M. ; San, Hong ; Leung, Kwanyee ; Parmacek, Michael S. ; Nabel, Elizabeth G. ; Nabel, Gary J. / Restricted expression of an adenoviral vector encoding fas ligand (CD95L) enhances safety for cancer gene therapy. In: Molecular Therapy. 2000 ; Vol. 1, No. 6. pp. 555-565.
@article{9c942b9b2eba412784d2b08dc731c704,
title = "Restricted expression of an adenoviral vector encoding fas ligand (CD95L) enhances safety for cancer gene therapy",
abstract = "Gene transfer of Fas ligand (CD95L) using adenoviral vectors has been shown to generate apoptotic responses and potent inflammatory reactions that can be used to induce the regression of malignancies in vivo, but these vectors also cause significant hepatotoxicity that may limit their clinical utility. Here we describe an adenoviral vector encoding CD95L with restricted gene expression that reduces itstoxicity in vivo. Preclinical efficacy and gene expression studies of lineage-restricted CD95L adenoviral vectors were performed. To enhance its cytotoxicity and reduce potential systemic effects, a noncleavable CD95L was made by deleting a segment containing the cleavage site (CD95LΔQP). Higher CD95L expression of this mutant was observed on the tumor cell surface, together with a reduction in the release of soluble CD95L This CD95L cleavage mutant was then expressed under control of a smooth muscle-specific promoter, SM22α, and analyzed for its ability to suppress the growth of tumors of smooth muscle origin in vivo. Growth of human leiomyosarcomas but not gliomas was inhibited after ADV gene transfer into tumor-bearing immunodeficient mice. In contrast to viral promoters, in which mortality was uniformly seen after injection of 1012 particles, no significant hepatic injury or systemic toxicity was observed in mice, and the maximum tolerated dose was increased ≥10-to 100-fold. These findings suggest that restricted specif icity of adenoviral CD95Lgene expression enhances the safety of this approach for cancer gene therapy.",
keywords = "Adenoviral vectors, Cancer gene therapy, CD95L, Cleavage mutant, Fas ligand, Leiomyosarcoma, SM22α promoter, Smooth muscle cell",
author = "Kazunori Aoki and Aky{\"u}rek, {Levent M.} and Hong San and Kwanyee Leung and Parmacek, {Michael S.} and Nabel, {Elizabeth G.} and Nabel, {Gary J.}",
year = "2000",
month = "6",
language = "English (US)",
volume = "1",
pages = "555--565",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Restricted expression of an adenoviral vector encoding fas ligand (CD95L) enhances safety for cancer gene therapy

AU - Aoki, Kazunori

AU - Akyürek, Levent M.

AU - San, Hong

AU - Leung, Kwanyee

AU - Parmacek, Michael S.

AU - Nabel, Elizabeth G.

AU - Nabel, Gary J.

PY - 2000/6

Y1 - 2000/6

N2 - Gene transfer of Fas ligand (CD95L) using adenoviral vectors has been shown to generate apoptotic responses and potent inflammatory reactions that can be used to induce the regression of malignancies in vivo, but these vectors also cause significant hepatotoxicity that may limit their clinical utility. Here we describe an adenoviral vector encoding CD95L with restricted gene expression that reduces itstoxicity in vivo. Preclinical efficacy and gene expression studies of lineage-restricted CD95L adenoviral vectors were performed. To enhance its cytotoxicity and reduce potential systemic effects, a noncleavable CD95L was made by deleting a segment containing the cleavage site (CD95LΔQP). Higher CD95L expression of this mutant was observed on the tumor cell surface, together with a reduction in the release of soluble CD95L This CD95L cleavage mutant was then expressed under control of a smooth muscle-specific promoter, SM22α, and analyzed for its ability to suppress the growth of tumors of smooth muscle origin in vivo. Growth of human leiomyosarcomas but not gliomas was inhibited after ADV gene transfer into tumor-bearing immunodeficient mice. In contrast to viral promoters, in which mortality was uniformly seen after injection of 1012 particles, no significant hepatic injury or systemic toxicity was observed in mice, and the maximum tolerated dose was increased ≥10-to 100-fold. These findings suggest that restricted specif icity of adenoviral CD95Lgene expression enhances the safety of this approach for cancer gene therapy.

AB - Gene transfer of Fas ligand (CD95L) using adenoviral vectors has been shown to generate apoptotic responses and potent inflammatory reactions that can be used to induce the regression of malignancies in vivo, but these vectors also cause significant hepatotoxicity that may limit their clinical utility. Here we describe an adenoviral vector encoding CD95L with restricted gene expression that reduces itstoxicity in vivo. Preclinical efficacy and gene expression studies of lineage-restricted CD95L adenoviral vectors were performed. To enhance its cytotoxicity and reduce potential systemic effects, a noncleavable CD95L was made by deleting a segment containing the cleavage site (CD95LΔQP). Higher CD95L expression of this mutant was observed on the tumor cell surface, together with a reduction in the release of soluble CD95L This CD95L cleavage mutant was then expressed under control of a smooth muscle-specific promoter, SM22α, and analyzed for its ability to suppress the growth of tumors of smooth muscle origin in vivo. Growth of human leiomyosarcomas but not gliomas was inhibited after ADV gene transfer into tumor-bearing immunodeficient mice. In contrast to viral promoters, in which mortality was uniformly seen after injection of 1012 particles, no significant hepatic injury or systemic toxicity was observed in mice, and the maximum tolerated dose was increased ≥10-to 100-fold. These findings suggest that restricted specif icity of adenoviral CD95Lgene expression enhances the safety of this approach for cancer gene therapy.

KW - Adenoviral vectors

KW - Cancer gene therapy

KW - CD95L

KW - Cleavage mutant

KW - Fas ligand

KW - Leiomyosarcoma

KW - SM22α promoter

KW - Smooth muscle cell

UR - http://www.scopus.com/inward/record.url?scp=0034200933&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034200933&partnerID=8YFLogxK

M3 - Article

C2 - 10933980

AN - SCOPUS:0034200933

VL - 1

SP - 555

EP - 565

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 6

ER -